Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 30, 2024, titled "Zydus Lifesciences launches Rexigo , the oral once-a-day pill for advanced prostate cancer patients in India".
Zydus Lifesciences Limited Press Release Jan 30 2024
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing the launch of Rexigo™, an oral once-a-day pill for advanced prostate cancer patients in India. This therapy is significant as it suppresses testosterone levels, providing a more convenient alternative to previous injectable treatments. Rexigo™ is the first generic oral option available in India, making it both accessible and affordable for patients. The launch marks a major advancement in prostate cancer management, offering improved safety and quality of life for patients.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Jan 25 2024
- Press Release Jan 19 2024
- Press Release Jan 17 2024
- Press Release Dec 22 2023
- Press Release Dec 16 2023
Later from Zydus Lifesciences
- Press Release Feb 08 2024
- Press Release Feb 09 2024
- Press Release Feb 16 2024
- Zydus Lifesciences Limited Press Release Feb 26 2024
- Press Release Mar 13 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences